Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

NOZAKI=8.1A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO 10/721,742 **Application Number** INFORMATION DISCLOSURE Filing Date November 26, 2003 Masako NOZAKI STATEMENT BY APPLICANT First Named Inventor 1614 APR 0 2 2004 **Group Art Unit** (use as many sheets as necessary) **Examiner Name** LESUE A.KOY

Sheet

Attorney Docket Number

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
IN	AC	XP-001184701 ABSTRACT, HIRABAYASHI et al., Cysteinyl leukotrienes activate microglia through the CYSLT1 receptor, Society for Neuroscience, 27(1)1160 (Nov. 10, 2001).	
		A ron	
Eva	iner/		
Exam		Date Considered 09 MAY 2086	

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Co	omplete if Known	
Substitution for form 144074			Application Number	NOT YET ASSIGNED 101721742	
<b>INFORMATIO</b>	ON DISC	LOSURE	Filing Date	ON EVEN DATE HEREWITH 26 NOV 2	2003
STATEMENT	RY AP	PLICANT	First Named Inventor Masako NOZAKI		
O I A I E III E I I	<b>3</b> . ,		Group Art Unit	1614	
(use as many sheets as necessary)			Examiner Name	LESLIE A. ROYDS	
Sheet 1	of	1	Attorney Docket Number	NOZAKI=8.1A	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
UAR	AA	Zeng et al., Yao Xue Xue Bao, Protective Effect of ONO-1078, A Leukotriene Antagonis on Foca Cerebral Ischemia in Mice, Acta.  Pharamaceutics Sinica, 36(2):148-150 (2001) ABSTRACT	
LAR	АВ	Zhang, W., et al., Neuroprotective Effect of ONO-1078, A Leukotriene Receptor Antagonist, on Focal Cerebral Ischemia in Rats, Acta Pharmacol Sin, 23(10):871-877 (2002)	_
-			/
_			
/		11.0h	
Exami Signat		Date Considered 19 MAY 2001	

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for	form	1449A/PTO	

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of 1

(use as many sheets as necessary)

Co		
Application Number	10/721,742	
Filing Date	November 26, 2003	
First Named Inventor	Masako NOZAKI	
Group Art Unit	1614	
Examiner Name	LESUEARDYDS	***************************************
Attorney Docket Number	NOZAKI=8.1A	

**U.S. PATENT DOCUMENTS** Document Number Publication Date Name of Patentee or Pages, Columns, Lines, Where MM-DD-YYYY Cite Applicant of Cited Document Relevant Passages or Relevant xaminer Number-Kind Code<sup>2 (if long</sup> No.1 Figures Appear Initials\* ΑD US-2002/0123520 A1 09-05-2002 MARFAT et al. LAN US-5,441,951 08-15-1995 SERHAN ΑE ΑF US-5,079,261 01-07-1992 SERHAN et al.

		FOREIC	ON PATENT DO	CUMENTS		
F	Cite	Foreign Patent Number  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant Passages	
Examiner Initials*	No.1	(a. a.a)	MM-DD-YYYY	Cited Document	or Relevant Figures . Appear	T⁰
LAR	- AG	EP 0905133 A1	03-31-1999	KOWA CO. LTD.		-
LAR	АН	EP 0528337 A1	02-24-1993	FUJISAWA PHARMACEUTICAL CO., LTD.	-	-
LAR	Al	EP 0351856 A2	01-24-1990	TAKEDA CHEMICAL INDUSTRIES, LTD.	_	-
LANZ	AJ	EP 1424101 A2	06-02-2004	NOZAKI		_
HAR	AK	WO 99/21007	04-29-1999	PHARMAPRINT, INC.		-
LAR	AL	WO 02/060875 A1	08-08-2002	PFIZER PRODUCTORS INC.		_

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²			
M	ΑM	ALVAREZ LOSADA, Role of platelet-activating factor, eicosanoids and bradykinin in adjuvant therapy for sepsis, Acta Perdiatrica Espanola, 60(9):535-544 (2002)	ABS			
HAR	AN	BEERS AND BERKOW, Merck manual of diagnosis and therapy, Merck Research Laboratories, 1435-1437 (1999)	_			
MR	AO	KOBAYASHI et al., Effect of leukotriene antagonist on experimental delayed cerebral vasospasm, Neurosurgery, 31(3):550-556 (1992)	)			
100	AP	MATSUO et al., Leukotriene B₄ and C₄ in cerebrospinal fluid from children with meningitis and febrile seizures, Pediatric Neurology, 14(2):121-124 (1996)	_			
LARE	AQ	NEUWELT et al., Use of enhanced computerized tomography to evaluate osmotic blood-brain barrier disruption, Neurosurgery, 6(1):49-56 (1980)	)			
LAR	AR	OGATA et al., Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pretreated mice, Infection and Immunity, 60(6):2432-2437 (1992)	_			
LIPE	AS	YOSHIKAWA et al., Effect of platelet-activating factor antagonist and leukotriene antagonist on endotoxin shock in the rat: role of the leukocyte, Circulatory Shock, 38:29-33 (1992)	1			
LAR	AT	Is there a therapeutic role for blood-brain barrier disruption? Annals of Internal Medicine, 93(1):137-139 (1980)				
MAR	AU	Abstract- XP002284974 Denient Publications Ltd. (1996)	_			

Examiner Date 09 MAY 2006 Signature Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.